NovoSeven® (Novo Nordisk, Denmark) is a recombinant DNA preparation of activated blood coagulation factor VII (rFVIIa). It is used to manage bleeding in hemophilia patients for whom standard therapy is inadequate because of the presence of inhibitors to either factor VIII (hemophilia A) or factor IX (hemophilia B). It poses no risk for the transmission of human pathogens, and it is infused in r...

The Questions: (1) Should the patient receive vitamin K and fresh-frozen plasma on evaluation in the emergency department to reverse international normalized ratio? (2) If so, what is the appropriate targeted international normalized ratio level? (3) Should other hemostatic agents such as prothrombin complex concentrates or NovoSeven be used instead of (or in combination with) fresh-frozen plasma?

INTRODUCTION Factor VII deficiency is a rare cause of haemorrhagic syndrome. The Authors describe a case of a 46 years old patient with congenital factor VII deficiency that successfully underwent breast surgery after treatment with Novoseven® before the procedure. MATERIALS AND METHODS The AA used the schedule reported below to value the levels of PT and aPTT in the patient. Blood Collection...

Following the publication of the above article [1], we noticed that the Competing interests section was incorrect and should read as follows: RMG has worked as a consultant for Novo Nordisk and lectured on behalf of Novo Nordisk about NovoSeven. References 1. Grounds RM, Bolan C: Clinical experiences and current evidence for therapeutic recombinant factor VIIa treatment in nontrauma settings.

Recombinant activated factor VII (rFVIIa, NovoSeven) has been successfully used to treat bleeding episodes in patients with antibodies against coagulation factors VIII and IX. In recent years, rFVIIa has also been employed for the management of uncontrolled bleeding in a number of congenital and acquired haemostatic abnormalities. Based on a literature search, this review examines the current k...

Significant post-operative bleeding can be encountered in a small population of pediatric surgical patients requiring cardiopulmonary bypass (CPB). Recombinant factor VIIa (NovoSeven) has been advocated as a possible off-label rescue therapy for these individuals when conventional blood component therapy alone is inadequate. This study retrospectively evaluates rFVIIa administration for the tre...

EVIDENCE DEFINITIONS • Class I: Prospective randomized controlled trial. • Class II: Prospective clinical study or retrospective analysis of reliable data. Includes observational, cohort, prevalence, or case control studies. • Class III: Retrospective study. Includes database or registry reviews, large series of case reports, expert opinion. • Technology assessment: A technology study which doe...

A 69-year-old male, who underwent cardio-pulmonary bypass surgery, required biventricular support using the Abiomed. The patient subsequently developed a consumptive coagulopathy. The thromboelastograph was used to administer NovoSeven and guide allogenic transfusions to achieve a hematocrit of greater than 30% and a platelet count greater than 100,000 per microL. Disseminated intravascular coa...

Factor V deficiency secondary to inhibitors is extremely rare and can be caused by a wide collection of exposures such as bovine thrombin and beta lactamase antibiotics. The management of factor V deficiency with inhibitor is a condition treated based on case reports due to the rarity of this condition. We describe a complicated case of an elderly patient with severe factor V deficiency with hi...